[Amivantamab (NSCLC, pretreated) – Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018014216
German
Original Title: Amivantamab (NSCLC, vorbehandelt, Kombination mit Carboplatin und Pemetrexed)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a25-09.html
Year Published: 2025
URL for published report: https://www.iqwig.de/download/a25-09_amivantamab_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A25-09
MeSH Terms
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Carboplatin
  • Antibodies, Bispecific
  • Antineoplastic Agents, Immunological
  • Pemetrexed
  • Antineoplastic Combined Chemotherapy Protocols
Keywords
  • Amivantamab
  • Carboplatin
  • Pemetrexed
  • Carcinoma – Non-Small-Cell Lung
  • Benefit Assessment
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.